Appropriateness of Empirical Treatment and Outcome in Bacteremia Caused by Extended-Spectrum-β-Lactamase-Producing Bacteria

ABSTRACT We studied clinical characteristics, appropriateness of initial antibiotic treatment, and other factors associated with day 30 mortality in patients with bacteremia caused by extended-spectrum-β-lactamase (ESBL)-producing bacteria in eight Dutch hospitals. Retrospectively, information was collected from 232 consecutive patients with ESBL bacteremia (due to Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae) between 2008 and 2010. In this cohort (median age of 65 years; 24 patients were <18 years of age), many had comorbidities, such as malignancy (34%) or recurrent urinary tract infection (UTI) (15%). One hundred forty episodes (60%) were nosocomial, 54 (23%) were otherwise health care associated, and 38 (16%) were community acquired. The most frequent sources of infection were UTI (42%) and intra-abdominal infection (28%). Appropriate therapy within 24 h after bacteremia onset was prescribed to 37% of all patients and to 54% of known ESBL carriers. The day 30 mortality rate was 20%. In a multivariable analysis, a Charlson comorbidity index of ≥3, an age of ≥75 years, intensive care unit (ICU) stay at bacteremia onset, a non-UTI bacteremia source, and presentation with severe sepsis, but not inappropriate therapy within <24 h (adjusted odds ratio [OR], 1.53; 95% confidence interval [CI], 0.68 to 3.45), were associated with day 30 mortality. Further assessment of confounding and a stratified analysis for patients with UTI and non-UTI origins of infection did not reveal a statistically significant effect of inappropriate therapy on day 30 mortality, and these results were insensitive to the possible misclassification of patients who had received β-lactam–β-lactamase inhibitor combinations or ceftazidime as initial treatment. In conclusion, ESBL bacteremia occurs mostly in patients with comorbidities requiring frequent hospitalization, and 84% of episodes were health care associated. Factors other than inappropriate therapy within <24 h determined day 30 mortality.

[1]  A P MacGowan,et al.  EUCAST expert rules in antimicrobial susceptibility testing. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  M. Bonten,et al.  Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. , 2012, The Journal of antimicrobial chemotherapy.

[3]  R. Bonomo,et al.  Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Rodríguez-Baño,et al.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Herman Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. , 2011, The Journal of antimicrobial chemotherapy.

[6]  Hsing-Chun Chung,et al.  Bacteremia Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli Sequence Type ST131 and Non-ST131 Clones: Comparison of Demographic Data, Clinical Features, and Mortality , 2011, Antimicrobial Agents and Chemotherapy.

[7]  F. G. Rosa,et al.  The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria , 2011, Infection.

[8]  W. Ko,et al.  Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[9]  G. Peirano,et al.  Clinical and Molecular Characteristics of Extended-Spectrum- β-Lactamase-Producing Escherichia coli Causing Bacteremia in the Rotterdam Area, Netherlands , 2011, Antimicrobial Agents and Chemotherapy.

[10]  Clsi.  Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement , 2010 .

[11]  Y. Carmeli,et al.  National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases , 2010, Antimicrobial Agents and Chemotherapy.

[12]  Leonard Leibovici,et al.  Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis , 2010, Antimicrobial Agents and Chemotherapy.

[13]  O. Cars,et al.  Foreign Travel Is a Major Risk Factor for Colonization with Escherichia coli Producing CTX-M-Type Extended-Spectrum β-Lactamases: a Prospective Study with Swedish Volunteers , 2010, Antimicrobial Agents and Chemotherapy.

[14]  A. Oliver,et al.  Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli , 2010, Journal of Clinical Microbiology.

[15]  J. Pitout.  Infections with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae , 2010, Drugs.

[16]  Y. Carmeli,et al.  A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Á. Soriano,et al.  Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. , 2009, The Journal of antimicrobial chemotherapy.

[18]  D. Church,et al.  Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. , 2008, The Journal of infection.

[19]  A. Oliver,et al.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. , 2008, Archives of internal medicine.

[20]  G. Fadda,et al.  Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy , 2008, Antimicrobial Agents and Chemotherapy.

[21]  J. Pitout.  Faculty Opinions recommendation of Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. , 2008 .

[22]  G. Petrikkos,et al.  Enterobacteriaceae Bloodstream Infections: Presence of Integrons, Risk Factors, and Outcome , 2007, Antimicrobial Agents and Chemotherapy.

[23]  G. Fadda,et al.  Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment , 2007, Antimicrobial Agents and Chemotherapy.

[24]  A. Voss,et al.  Dutch Guideline for Preventing Nosocomial Transmission of Highly Resistant Microorganisms (HRMO) , 2005, Infection.

[25]  Sung-Han Kim,et al.  Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on Antimicrobial Therapy , 2004, Antimicrobial Agents and Chemotherapy.

[26]  J. Rello,et al.  Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. , 2003, Chest.

[27]  G Sherman,et al.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.

[28]  S. Bhagwanjee,et al.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. , 1997, Critical care medicine.

[29]  M. Bonten,et al.  Multi-centre evaluation of a phenotypic extended spectrum β-lactamase detection guideline in the routine setting. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  Geert Molenberghs,et al.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). , 2011, The Journal of antimicrobial chemotherapy.

[31]  P. Pickkers,et al.  Antibacterial therapy of adult patients with Sepsis , 2010 .

[32]  H. Goossens,et al.  International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum -Lactamase Production in Nosocomial Infections , 2004, Annals of Internal Medicine.

[33]  Daniel J Sexton,et al.  Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.

[34]  J. Ariza,et al.  An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. , 2001, The Journal of hospital infection.

[35]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[36]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.